E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Initial stage cohort: SCLC germline BRCA mutated (gBRCAm) metastatic human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) gBRCAm platinum sensitive relapsed ovarian cancer (OvC) gastric cancer Second stage cohort: BRCAm platinum sensitive relapsed OvC non BRCAm platinum sensitive relapsed OvC Third stage cohort: HER2-negative, BRCAm BC HER2 negative, non BRCAm, Homologous Recombination Repair gene mutated (HRRm) BC non BRCAm, non HRRm triple negative BC |
|
E.1.1.1 | Medical condition in easily understood language |
Patients will have the following types of advanced or metastatic cancer: - small cell lung cancer - breast cancer - ovarian cancer - gastric cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10033130 |
E.1.2 | Term | Ovarian cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071114 |
E.1.2 | Term | Metastatic gastric adenocarcinoma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027475 |
E.1.2 | Term | Metastatic breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10041071 |
E.1.2 | Term | Small cell lung cancer stage unspecified |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of MEDI4736 in combination with olaparib ± bevacizumab on Disease Control Rate in patients with selected advanced solid tumors To assess the safety and tolerability of MEDI4736 in combination with olaparib ± bevacizumab in patients with selected advanced solid tumors |
|
E.2.2 | Secondary objectives of the trial |
To investigate the preliminary antitumor activity of MEDI4736 in combination with olaparib ± bevacizumab in patients with selected advanced solid tumors. To determine plasma conc of olaparib after single and multiple dosing when given orally to patients alone and in combination with MEDI4736 ± bevacizumab. To characterize the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and multiple dosing when given intravenously to patients in combination with olaparib±bevacizumab. To characterize the PK and pharmacodynamics of bevacizumab after single dosing and multiple dosing when given i.v. to patients in combination with MEDI4736 and olaparib To evaluate candidate predictive biomarkers of treatment effect such as, but not limited to, PD-L1 expression Exploratory: To evaluate baseline measures and changes induced by olaparib alone in combination with MEDI4736 ± bevacizumab, in peripheral blood, archival tumor, and tumor biopsies (frozen and fix |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria are presented separately for each cohort of Modules 1 to 10 Small cell lung cancer cohort: Patients must have histologically or cytologically confirmed progressive metastatic or recurrent solid tumor (as defined below for each tumor type). To be enrolled in the SCLC cohort, only the tumor types and settings described below are allowed (see in the Protocol) At least 1 measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib. Biomarker-only disease is not considered evaluable. Breast cancer cohort: Patients must have histologically or cytologically confirmed progressive metastatic or recurrent solid tumor (as defined below for each tumor type). To be enrolled in the gBRCAm breast cancer cohort, only the tumor types and settings described below are allowed (see in the Protocol). At least 1 measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib. Biomarker-only disease is not considered evaluable. gBRCAm human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with metastatic or locally advanced disease, which is unresectable (or the patient is not a candidate for resection), may be first, second or third line but all patients must meet the following specific criteria: Must have confirmation of a germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Must have previously received treatment with an anthracycline (eg, doxorubicin, epirubicin) unless contraindicated and/or a taxane (eg, paclitaxel, docetaxel) in either a neo-adjuvant/adjuvant or metastatic setting. gBRCAm ovarian cancer cohort: Patients must have histologically or cytologically confirmed progressive metastatic or recurrent solid tumor (as defined below for each tumor type). To be enrolled in the gBRCAm ovarian cancer cohort, only the tumor types and settings described below are allowed (see in the Protocol). At least 1 measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib. Biomarker-only disease is not considered evaluable. non-gBRCA ovarian cancer High grade serous ovarian cancer (including patients with primary peritoneal and/or fallopian tube cancer) with recurrent disease and: Previously received 1 or 2 previous lines of chemotherapy, including ≥1 line of platinum-based therapy. NOTE: Adjuvant, neo-adjuvant, or maintenance treatment administered as part of a chemotherapy regimen would not be considered as separate line of therapy Gastric cancer cohort: Patients must have histologically or cytologically confirmed progressive metastatic or recurrent solid tumor (as defined below for each tumor type). To be enrolled in the gastric cancer cohort, only the tumor types and settings described below are allowed (see in the Protocol). At least 1 measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib. Biomarker-only disease is not considered evaluable. Metastatic or recurrent gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma) that has progressed following first-line therapy, confirmed by imaging modalities: The first-line regimen must have contained at least a doublet 5- fluoropyrimidine and platinum based regimen. Capecitabine is an acceptable 5-fluoropyrimidine-containing agent. Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy containing doublet 5-fluoropyrimidine and platinum based regimen is considered as first-line therapy. BRCAm Breast Cancer Expansion Cohort,Triple-negative Breast Cancer Triplet Cohort & HRRm breast cancer cohort Patients must have histologically or cytologically confirmed progressive metastatic or recurrent solid tumor (as defined in the Protocol for each tumor type).
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria are presented separately for each cohort in Modules 1 to 9 Small cell lung cancer cohort: Prior chemotherapy or other systemic anticancer therapy (eg, targeted biotherapy or hormonal agents) within 4 weeks prior to start of olaparib treatment; 6 weeks for nitrosoureas or mitomycin. Exceptions and treatments of particular importance are noted below (see Protocol) Radiation therapy within 4 weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start. Patients with mixed small cell and non-small cell lung cancer histology. Breast cancer cohort: Prior chemotherapy or other systemic anticancer therapy (eg, targeted biotherapy or hormonal agents) within 4 weeks prior to start of olaparib treatment; 6 weeks for nitrosoureas or mitomycin. Exceptions and treatments of particular importance are noted below (see the Protocol). Radiation therapy within 4 weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start. Patients with HER2-positive disease (3+ by immunohistochemistry [IHC] or in situ hybridization amplified ≥2.0). Patients cannot have received more than 2 prior lines of cytotoxic chemotherapy for metastatic disease. Prior treatments with hormonal therapy and non-hormonal targeted therapy are allowed and not counted as a prior line of cytotoxic chemotherapy. For the purposes of this protocol, the combination of an aromatase inhibitor and everolimus or palbociclib, are not considered cytotoxic chemotherapy. BRCA1 and/or BRCA2 variants that are considered to be non-detrimental (eg, "Variants of uncertain clinical significance" or "Variant of unknown significance" or "Variant, favor polymorphism" or "benign polymorphism" etc). gBRCAm ovarian cancer cohort: Prior chemotherapy or other systemic anticancer therapy (eg, targeted biotherapy or hormonal agents) within 4 weeks prior to start of olaparib treatment; 6 weeks for nitrosoureas or mitomycin. Exceptions and treatments of particular importance are noted below (see in the Protocol). Radiation therapy within 4 weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start. Patients with germline BRCA1 and/or BRCA2 variants that are considered to be non-detrimental (eg, "Variants of uncertain clinical significance" or "Variant of unknown significance" or "Variant, favor polymorphism" or "benign polymorphism" etc). non-gBRCA ovarian Patients with known germline BRCA1 and/or BRCA2 mutations, with the exception of variants of "uncertain clinical significance" or "Variant of unknown significance" or "Variant, favor polymorphism" or "benign polymorphism. Gastric cancer cohort: Prior chemotherapy or other systemic anticancer therapy (eg, targeted biotherapy or hormonal agents) within 4 weeks prior to start of olaparib treatment; 6 weeks for nitrosoureas or mitomycin. Exceptions and treatments of particular importance are noted below (see in the Protocol). Radiation therapy within 4 weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start For HER2-negative patients: More than 1 prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy with more than 6 months wash-out period) for the treatment of gastric cancer in the metastatic or recurrent setting. For HER2-positive patients: More than 2 prior chemotherapy regimens (except for adjuvant/neoadjuvant with more than 6 months wash-out period) for the treatment of gastric cancer in the metastatic or recurrent setting. Intestinal obstruction or CTCAE grade 3 or grade 4 upper gastrointestinal bleeding within 4 weeks before the study entry BRCAm breast expansion cohort & HRRm breast cohort Prior chemotherapy or other systemic anticancer therapy (eg, targeted biotherapy or hormonal agents) within 4 weeks prior to start of study treatment; 6 weeks for nitrosoureas or mitomycin. Anti-hormonal treatment for breast cancer is allowed until 7 days prior to study treatment. Triple-negative Breast Cancer Triplet Cohort Prior chemotherapy or other systemic anticancer therapy (eg, targeted biotherapy or hormonal agents) within 4 weeks prior to start of study treatment; 6 weeks for nitrosoureas or mitomycin. Exposure to an investigational agent within 30 days or 5 half-lives (whichever is the longer) prior to start of study treatment is not allowed Prior receipt of biologics targeting T-cell co-regulatory proteins and/or immune checkpoints is not allowed Radiation therapy within 4 weeks prior to start of study treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Initial Stage Cohorts: Disease Control Rate (CR+PR+SD) based on modified RECIST 1.1 at 12 weeks Secondary Stage Cohorts: BRCAm cancer expansion cohort: ORR (CR+PR) based on modified RECIST 1.1 assessed by Inv. Ovarian cancer triplet and doublet cohorts: DCR (CR+PR+SD) based on modified RECIST 1.1 at 24 weeks Third stage cohorts: BRCAm breast cancer expansion cohort: ORR (CR+PR) based on RECIST 1.1 assessed by Inv. HRRm breast cancer and TNBC triplet cohorts: DCR (CR+PR+SD) based on RECIST at 16 weeks All cohorts: AEs vital signs, including blood pressure, pulse, ECG and laboratory findings (including clinical chemistry and hematology) irAEs: given the intended mechanisms of action of MEDI4736, particular attention will be given to AEs that may follow enhanced T-cell activation or other irAE Dose interruptions, dose reductions Causes of olaparib and MEDI4736 discontinuation Secondary and Third Stage Cohorts: Triplet cohorts only: Causes of bevacizumab discontinuation |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Initial Stage Cohorts: DCR (CR+PR+SD) based on modified RECIST 1.1 at 12 weeks Secondary Stage Cohorts: BRCAm ovarian cancer expansion cohort: ORR (CR+PR) based on modified RECIST 1.1 assessed by Inv. Ovarian cancer triplet and doublet cohorts: DCR (CR+PR+SD) based on modified RECIST at 24 weeks Third Stage Cohorts: BRCAm breast cancer expansion cohort: ORR (CR+PR) based on RECIST 1.1 assessed by Inv. every 8 weeks until objective disease progression and analyzed when all 80 patients have been followed for a min. of 24, 40, 56, 80 and 104 weeks HRRm breast cancer and TNBC triplet cohorts: DCR (CR+ PR+SD) based on RECIST 1.1 at 16 weeks |
|
E.5.2 | Secondary end point(s) |
Initial Stage Cohorts: DCR at 28 weeks* ORR (CR+PR) based on modified RECIST 1.1* DoR based on modified RECIST 1.1* PFS based on modified RECIST 1.1* *Assessed by the investigator in all Initial Stage Cohorts. Also assessed by BICR in the gBRCAm ovarian cancer cohort Percentage change from baseline in tumor size at 12 weeks and 28 weeks Best percentage change from baseline in tumor size Time to study treatment discontinuation Overall survival BRCAm ovarian cancer expansion cohort: DCR at 24 weeks and 56 weeks** DoR based on modified RECIST 1.1** PFS based on modified RECIST 1.1** **Assessed by the investigator and assessed by BICR ORR (CR+PR) based on modified RECIST 1.1 assessed by BICR Percentage change from baseline in tumor size at 24 weeks and 56 weeks Best percentage change from baseline in tumor size TDT Overall survival Ovarian cancer triplet and doublet cohorts: DCR at 56 weeks DoR based on modified RECIST 1.1 PFS based on modified RECIST 1.1 ORR (CR+PR) based on modified RECIST 1.1 assessed by the Inv. Percentage change from baseline in tumor size at 24 and 56 weeks Best percentage change from baseline in tumor size TDT Overall survival Third Stage Cohorts: BRCAm breast cancer expansion cohort DCR and 16 and 24 weeks** DoR based on modified RECIST 1.1** PFS based on modified RECIST 1.1** **assessed by the Inv. and by BICR ORR (CR+PR) based on RECIST 1.1 assessed by BICR Percentage change from baseline in tumor size at 24 and 56 weeks Best percentage change from baseline in tumor size TDT Overall survival HRRm breast cancer and TNBC triplet cohorts: DCR at 24 weeks DoR based on RECIST 1.1 PFS based on RECIST 1.1 ORR (CR+PR) based on RECIST 1.1 assessed by the Inv. Percentage change from baseline in tumor size at weeks 24 and 56 Best percentage change from baseline in tumor size TDT Overall survival |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Initial Stage Coh:DCR at 28weeks(w),DoR,PFS,ORR,OS* ,TDT**,Percentage change(PC) from baseline in tumor at 12 and 28 w Second Stage Coh:BRCAm ov cancer expansion cohort:DCR at 24 and 56 w,DoR, PFS, ORR, OS*,TDT** Ovn cancer triplet and doublet coh:DCR at 56 wDoR,PFs,ORR,OS*,TDT**,PC from baseline in tumor at w24 and 56 Third stage coh:BRCAm breast cancer exp cohort:DCR at w16 and 24 w,DoR, PFS, ORR, OS* ,TDT** ,PC from baseline in tumor at weeks 24 and 56 HRRm breast cancer and TNBC triplet cohorts:DCR at w24,DoR, PFS, ORR,OS*,TDT**,PC from baseline in tumor at w24 and 56 *data obtained up until progression or last evaluable assessment in the absence of progression **data obtained up until treatment discontinuation or last recorded date on which the patient was know to be alive |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.1.7.1 | Other trial design description |
antitumor act of MEDI4736 in comb with ola in patients with metastatic or recurrent solid tumors |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Israel |
Korea, Republic of |
Netherlands |
Switzerland |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date of the last visit of the last patient occurring when all patients have completed study therapy. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |